Multi-target kinase inhibitor, pharmaceutical composition, and preparation method for multi-target kinase inhibitor and use thereof
US12201635B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Nov 27, 2019 |
| Grant date | Jan 21, 2025 |
| Priority date | — |
| Expiry date | Aug 31, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D239/88
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A multi-target kinase inhibitor is shown in formula (I), in which R is selected from formula (a), formula (b), formula (c), formula (d), formula (e) and formula (f). The multi-target kinase inhibitor can effectively inhibit the enzymatic activities of RET, VEGFR3 and PDGFRA, and can effectively treat diseases that are regulated and controlled by multi-target kinases and are related to abnormal signal transduction pathways of the multi-target kinases, including cancers of breast, respiratory tract, brain, reproductive organ, digestive tract, urinary tract, eye, liver, skin, head and/or neck and distant metastatic cancers thereof, and lymphoma, sarcoma, leukemia and the like. The active ingredients of the pharmaceutical composition of the present invention comprise a multi-target kinase inhibitor, which accounts for 1-50 wt % of the composition.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.